Unity Biotechnology Terminates Material Agreement
| Field | Detail |
|---|---|
| Company | Unity Biotechnology, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $3.65 million, $2.75 million, $0.90 million, $0.20 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, security-holder-rights
TL;DR
Unity Biotech terminated a big deal and changed some shareholder stuff. Details TBD.
AI Summary
Unity Biotechnology, Inc. announced on September 24, 2025, the termination of a material definitive agreement. The company also reported material modifications to the rights of its security holders. Specific details regarding the agreement and modifications were not provided in this filing.
Why It Matters
The termination of a material agreement and modifications to security holder rights can significantly impact a company's financial standing and strategic direction.
Risk Assessment
Risk Level: medium — Termination of material agreements and modifications to security holder rights can introduce uncertainty and potential financial repercussions.
Key Players & Entities
- Unity Biotechnology, Inc. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
FAQ
What was the material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify the name or details of the agreement.
What were the material modifications to the rights of security holders?
The filing indicates material modifications to the rights of security holders occurred, but does not provide specific details about these modifications.
When did the termination of the material agreement and modifications to security holder rights occur?
The earliest event reported in the filing occurred on September 24, 2025.
What is the principal executive office address for Unity Biotechnology, Inc.?
The address of the principal executive offices is 124 Washington Street, Suite 101, Foxborough, Massachusetts 02035.
What is Unity Biotechnology, Inc.'s IRS Employer Identification Number?
Unity Biotechnology, Inc.'s IRS Employer Identification Number is 26-4726035.
Filing Stats: 1,488 words · 6 min read · ~5 pages · Grade level 13.3 · Accepted 2025-09-26 17:08:35
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share * * As reported in the r
- $3.65 million — ny agreed to pay Landlord approximately $3.65 million as prepaid rent in fulfillment of its r
- $2.75 million — of its rent obligations, consisting of $2.75 million paid by the Company concurrently with t
- $0.90 million — of credit issued in the face amount of $0.90 million. Additionally, in connection with the
- $0.20 million — n Agreement, Subtenant paid the Company $0.20 million concurrently with execution of the Subl
- $0.73 m — letter of credit in the face amount of $0.73 million, which the Company is obligated t
- $26.9 m — ation up to a total aggregate amount of $26.9 million, which aggregate cap shall be red
Filing Documents
- d190494d8k.htm (8-K) — 34KB
- d190494dex41.htm (EX-4.1) — 7KB
- d190494dex101.htm (EX-10.1) — 46KB
- 0001193125-25-220778.txt ( ) — 217KB
- unbx-20250924.xsd (EX-101.SCH) — 2KB
- unbx-20250924_lab.xml (EX-101.LAB) — 18KB
- unbx-20250924_pre.xml (EX-101.PRE) — 11KB
- d190494d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Certificate of Dissolution as filed by Unity Biotechnology, Inc. with the Secretary of the State of Delaware, effective September 26, 2025 10.1* Lease Termination Agreement and Amendment, by and between Unity Biotechnology, Inc. and Bayside Area Development, LLC, dated September 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UNITY BIOTECHNOLOGY, INC. Date: September 26, 2025 By: /s/ Craig Jalbert Craig Jalbert President